388 related articles for article (PubMed ID: 33639572)
1. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
2. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
4. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
[TBL] [Abstract][Full Text] [Related]
5. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
6. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.
Pötter-Nerger M; Dutke J; Lezius S; Buhmann C; Schulz R; Gerloff C; Kuhle J; Choe CU
J Neural Transm (Vienna); 2022 Mar; 129(3):295-300. PubMed ID: 35072765
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
11. Blood neurofilament light chain in Parkinson's disease.
Buhmann C; Magnus T; Choe CU
J Neural Transm (Vienna); 2023 Jun; 130(6):755-762. PubMed ID: 37067597
[TBL] [Abstract][Full Text] [Related]
12. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
13. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.
Moccia M; Pappatà S; Picillo M; Erro R; Coda AR; Longo K; Vitale C; Amboni M; Brunetti A; Capo G; Salvatore M; Barone P; Pellecchia MT
J Neurol; 2014 Nov; 261(11):2112-8. PubMed ID: 25119838
[TBL] [Abstract][Full Text] [Related]
14. Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort.
Kim R; Lee J; Kim Y; Kim A; Jang M; Kim HJ; Jeon B; Kang UJ; Fahn S
Parkinsonism Relat Disord; 2018 Jun; 51():49-54. PubMed ID: 29523394
[TBL] [Abstract][Full Text] [Related]
15. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
Fiorenzato E; Antonini A; Bisiacchi P; Weis L; Biundo R
Mov Disord; 2021 Oct; 36(10):2303-2313. PubMed ID: 34124799
[TBL] [Abstract][Full Text] [Related]
17. Associations of sleep disorders with serum neurofilament light chain levels in Parkinson's disease.
Qi WY; Sun Y; Guo Y; Tan L
BMC Neurol; 2024 May; 24(1):147. PubMed ID: 38693483
[TBL] [Abstract][Full Text] [Related]
18. Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.
Liu R; Umbach DM; Tröster AI; Huang X; Chen H
Parkinsonism Relat Disord; 2020 Mar; 72():23-30. PubMed ID: 32092703
[TBL] [Abstract][Full Text] [Related]
19. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
Yang Z; Xie Y; Dou K; Yang L; Xie A
Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
[TBL] [Abstract][Full Text] [Related]
20. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
